Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand

Journal of Innate Immunity

Volumn 6, Issue 3, 2014, Pages 315-324

  Wu, Christina C N ^a   Crain, Brian ^a   Yao, Shiyin ^a   Sabet, Mojgan ^b   Lao, Fitzgerald S ^a   Tawatao, Rommel I ^a   Chan, Michael ^a   Smee, Donald F ^c   Julander, Justin G ^c   Cottam, Howard B ^a   Guiney, Donald G ^b   Corr, Maripat ^b   Carson, Dennis A ^a   Hayashi, Tomoko ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UTAH STATE UNIVERSITY   (United States)

Author keywords

Anthrax; Immunotherapy; Influenza; Phospholipid conjugation; Toll like receptor 7; Venezuelan equine encephalitis; Virus infection

Indexed keywords

1V 270; CHEMOATTRACTANT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOMODULATING AGENT; INTERLEUKIN 6; KERATINOCYTE CHEMOATTRACTANT; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; ADENINE; CYTOKINE; LIGAND; PHOSPHATIDIC ACID; PHOSPHOLIPID; PURINE DERIVATIVE; TMX201; TOLL LIKE RECEPTOR 7; ANTIINFECTIVE AGENT; GAMMA INTERFERON; GLYCOPROTEIN P 15095; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; B LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE SYNDROME; DENDRITIC CELL; DRUG CYTOTOXICITY; FEMALE; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLUENZA A (H1N1); INGUINAL LYMPH NODE; INNATE IMMUNITY; INTERNALIZATION; INTERSTITIAL INFLAMMATION; INTRAPULMONARY DRUG ADMINISTRATION; LUNG; LUNG EDEMA; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOSIS; LYMPHOID ORGAN; MAXIMUM TOLERATED DOSE; MEDIASTINUM LYMPH NODE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PLASMACYTOSIS; PRIORITY JOURNAL; PROTECTION; VENEZUELAN EQUINE ENCEPHALITIS; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BACILLUS ANTHRACIS; BAGG ALBINO MOUSE; BRONCHOALVEOLAR LAVAGE FLUID; C57BL MOUSE; COMMUNICABLE DISEASES; DISEASE MODEL; DRUG EFFECTS; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; INTRANASAL DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; METABOLISM; ORTHOMYXOVIRIDAE INFECTIONS; SYNTHESIS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; ANOREXIA; CELL MIGRATION; CELLULAR DISTRIBUTION; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; HOST; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA VIRUS A H1N1; LUNG INFECTION; MONONUCLEAR CELL; SURVIVAL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ADENINE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; BRONCHOALVEOLAR LAVAGE FLUID; COMMUNICABLE DISEASES; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; FEMALE; HUMANS; IMMUNITY, INNATE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INJECTIONS, SPINAL; LIGANDS; LUNG; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; ORTHOMYXOVIRIDAE INFECTIONS; PHOSPHATIDIC ACIDS; PHOSPHOLIPIDS; PURINES; TOLL-LIKE RECEPTOR 7;

EID: 84898601556     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000355217     Document Type: Article

References (57)

1. Williams AE, Edwards L, Humphreys IR, Snelgrove R, Rae A, Rappuoli R, Hussell T: Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J Immunol 2004; 173: 7435-7443.
2. O'Neill LA, Golenbock D, Bowie AG: The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 2013; 13: 453-460.
3. Kawai T, Akira S: Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34: 637-650.
4. Gürtler C, Bowie AG: Innate immune detection of microbial nucleic acids. Trends Microbiol 2013;21:413-420.
5. Hammerbeck DM, Burleson GR, Schuller CJ, Vasilakos JP, Tomai M, Egging E, Cochran FR, Woulfe S, Miller RL: Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res 2007; 73: 1-11.
6. Hutchens MA, Luker KE, Sonstein J, Nunez G, Curtis JL, Luker GD: Protective effect of Toll-like receptor 4 in pulmonary vaccinia infection. PLoS Pathog 2008; 4:e1000153.
7. Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, Das D, Sun LQ, Wang M, Salazar AM: Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 2009; 27: 3481-3483.
8. Abdul-Careem MF, Firoz Mian M, Gillgrass AE, Chenoweth MJ, Barra NG, Chan T, Al- Garawi AA, Chew MV, Yue G, van Roojen N, Xing Z, Ashkar AA: FimH, a TLR4 ligand, induces innate antiviral responses in the lung leading to protection against lethal influenza infection in mice. Antiviral Res 2011; 92: 346-355.
9. Nasirudeen AM, Wong HH, Thien P, Xu S, Lam KP, Liu DX: RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl Trop Dis 2011; 5:e926.
10. Shinya K, Okamura T, Sueta S, Kasai N, Tanaka M, Ginting TE, Makino A, Eisfeld AJ, Kawaoka Y: Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses. Virol J 2011; 8: 97.
11. Shinya K, Ito M, Makino A, Tanaka M, Miyake K, Eisfeld AJ, Kawaoka Y: The TLR4- TRIF pathway protects against H5N1 influenza virus infection. J Virol 2012; 86: 19-24.
12. Beckett EL, Phipps S, Starkey MR, Horvat JC, Beagley KW, Foster PS, Hansbro PM: TLR2, but not TLR4, is required for effective host defence against Chlamydia respiratory tract infection in early life. PLoS One 2012; 7:e39460.
13. St Paul M, Mallick AI, Read LR, Villanueva AI, Parvizi P, Abdul-Careem MF, Nagy E, Sharif S: Prophylactic treatment with Tolllike receptor ligands enhances host immunity to avian influenza virus in chickens. Vaccine 2012; 30: 4524-4531.
14. Tuvim MJ, Gilbert BE, Dickey BF, Evans SE: Synergistic TLR2/6 and TLR9 activation protects mice against lethal influenza pneumonia. PLoS One 2012; 7:e30596.
15. Tan AC, Mifsud EJ, Zeng W, Edenborough K, McVernon J, Brown LE, Jackson DC: Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice. Mol Pharm 2012; 9: 2710-2718.
16. Roquilly A, Broquet A, Jacqueline C, Gautreau L, Segain JP, de Coppet P, Caillon J, Altare F, Josien R, Asehnoune K: TLR-4 agonist in post-haemorrhage pneumonia: role of dendritic and natural killer cells. Eur Respir J 2013, E-pub ahead of print.
17. Engel AL, Holt GE, Lu H: The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol 2011; 4: 275-289.
18. Chan M, Hayashi T, Kuy CS, Gray CS, Wu CC, Corr M, Wrasidlo W, Cottam HB, Carson DA: Synthesis and immunological characterization of toll-like receptor 7 agonistic conjugates. Bioconjug Chem 2009; 20: 1194-1200.
19. Wu CC, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, Cottam HB, Carson DA: Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci USA 2007; 104: 3990-3995.
20. Agassandian M, Mallampalli RK: Surfactant phospholipid metabolism. Biochim Biophys Acta 2013; 1831: 612-625.
21. Belz GT, Smith CM, Kleinert L, Reading P, Brooks A, Shortman K, Carbone FR, Heath WR: Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc Natl Acad Sci USA 2004; 101: 8670-8675.
22. Sabet M, Cottam HB, Guiney DG: Modulation of cytokine production and enhancement of cell viability by TLR7 and TLR9 ligands during anthrax infection of macrophages. FEMS Immunol Med Microbiol 2006; 47: 369-379.
23. Datta SK, Sabet M, Nguyen KP, Valdez PA, Gonzalez-Navajas JM, Islam S, Mihajlov I, Fierer J, Insel PA, Webster NJ, Guiney DG, Raz E: Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci USA 2010; 107: 10638-10643.
24. Julander JG, Bowen RA, Rao JR, Day C, Shafer K, Smee DF, Morrey JD, Chu CK: Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Res 2008; 80: 309-315.
25. Bennett AM, Elvin SJ, Wright AJ, Jones SM, Phillpotts RJ: An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 2000; 19: 337-347.
26. Smee DF, von Itzstein M, Bhatt B, Tarbet EB: Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs. Antimicrob Agents Chemother 2012; 56: 6328-6333.
27. Holzinger D, Jorns C, Stertz S, Boisson-Dupuis S, Thimme R, Weidmann M, Casanova JL, Haller O, Kochs G: Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol 2007; 81: 7776-7785.
28. Burkhart CG: Reports of immunologic reactions to imiquimod: an assessment of actinic keratoses and treatment concerns in this era of litigation lotto. Dermatol Online J 2005; 11: 40.
29. Richwald GA: Imiquimod. Drugs Today (Barc) 1999; 35: 497-511.
30. Hayashi T, Cottam HB, Chan M, Jin G, Tawatao RI, Crain B, Ronacher L, Messer K, Carson DA, Corr M: Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7. Am J Physiol Regul Integr Comp Physiol 2008; 295:R123- R132.
31. h t t p : / / w w w . n i a i d . n i h . g o v / t o p i c s / biodefenserelated/biodefense/pages/cata. aspx.
32. Ryzhikov AB, Tkacheva NV, Sergeev AN, Ryabchikova EI: Venezuelan equine encephalitis virus propagation in the olfactory tract of normal and immunized mice. Biomed Sci 1991; 2: 607-614.
33. Schafer A, Brooke CB, Whitmore AC, Johnston RE: The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J Virol 2011; 85: 10682-10690.
34. Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, Kitchener HC, Einstein MH: Therapy of human papillomavirus- related disease. Vaccine 2012; 30(suppl 5):F71-F82.
35. Schon MP, Schon M: Imiquimod: mode of action. Br J Dermatol 2007; 157(suppl 2):8-13.
36. Kovach MA, Standiford TJ: Toll like receptors in diseases of the lung. Int Immunopharmacol 2011; 11: 1399-1406.
37. Schill T, Schon MP, Pletz N, Emmert S, Schon M: Stimulation of pulmonary immune responses by the TLR2/6 agonist MALP-2 and effect on melanoma metastasis to the lung. Exp Dermatol 2012; 21: 91-98.
38. Campbell JD, Cho Y, Foster ML, Kanzler H, Kachura MA, Lum JA, Ratcliffe MJ, Sathe A, Leishman AJ, Bahl A, McHale M, Coffman RL, Hessel EM: CpG-containing immunostimulatory DNA sequences elicit TNFalpha- dependent toxicity in rodents but not in humans. J Clin Invest 2009; 119: 2564-2576.
39. Beilharz MW, Cummins JM, Bennett AL: Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem Biophys Res Commun 2007; 355: 740-744.
40. Garcia-Sastre A, Biron CA: Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006; 312: 879-882.
41. Haasbach E, Droebner K, Vogel AB, Planz O: Low-dose interferon type I treatment is effective against H5N1 and swine-origin H1N1 influenza A viruses in vitro and in vivo. J Interferon Cytokine Res 2011; 31: 515-525.
42. Kugel D, Kochs G, Obojes K, Roth J, Kobinger GP, Kobasa D, Haller O, Staeheli P, von Messling V: Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J Virol 2009; 83: 3843-3851.
43. Scagnolari C, Trombetti S, Solda A, Selvaggi C, Monteleone K, Spano L, Pierangeli A, Clementi M, Turriziani O, Antonelli G: Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes. J Interferon Cytokine Res 2011; 31: 475-479.
44. Steel J, Staeheli P, Mubareka S, Garcia-Sastre A, Palese P, Lowen AC: Transmission of pandemic H1N1 influenza virus and impact of prior exposure to seasonal strains or interferon treatment. J Virol 2010; 84: 21-26.
45. Ioannidis I, Ye F, McNally B, Willette M, Flano E: Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol 2013; 87: 3261-3270.
46. Goulet ML, Olagnier D, Xu Z, Paz S, Belgnaoui SM, Lafferty EI, Janelle V, Arguello M, Paquet M, Ghneim K, Richards S, Smith A, Wilkinson P, Cameron M, Kalinke U, Qureshi S, Lamarre A, Haddad EK, Sekaly RP, Peri S, Balachandran S, Lin R, Hiscott J: Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PloS Pathog 2013; 9:e1003298.
47. Tate MD, Ioannidis LJ, Croker B, Brown LE, Brooks AG, Reading PC: The role of neutrophils during mild and severe influenza virus infections of mice. PLoS One 2011; 6:e17618.
48. Walberg K, Baron S, Poast J, Schwartz B, Izotova L, Pestka S, Peterson JW: Interferon protects mice against inhalation anthrax. J Interferon Cytokine Res 2008; 28: 597-601.
49. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR: Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003; 170: 5636-5643.
50. Sloat BR, Cui Z: Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine- DNA particles. Pharm Res 2006; 23: 262-269.
51. Lukaszewski RA, Brooks TJ: Pegylated alpha interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on the host immune response to infection. J Virol 2000; 74: 5006-5015.
52. Ryzhikov AB, Ryabchikova EI, Sergeev AN, Tkacheva NV: Spread of Venezuelan equine encephalitis virus in mice olfactory tract. Arch Virol 1995; 140: 2243-2254.
53. Aronson JF, Grieder FB, Davis NL, Charles PC, Knott T, Brown K, Johnston RE: A single- site mutant and revertants arising in vivo define early steps in the pathogenesis of Venezuelan equine encephalitis virus. Virology 2000; 270: 111-123.
54. Vogel P, Abplanalp D, Kell W, Ibrahim MS, Downs MB, Pratt WD, Davis KJ: Venezuelan equine encephalitis in Balb/c mice: kinetic analysis of central nervous system infection following aerosol or subcutaneous inoculation. Arch Pathol Lab Med 1996; 120: 164-172.
55. Charles PC, Walters E, Margolis F, Johnston RE: Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse. Virology 1995; 208: 662-671.
56. Grieder FB, Davis NL, Aronson JF, Charles PC, Sellon DC, Suzuki K, Johnston RE: Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 1995; 206: 994-1006.
57. Gleiser CA, Gochenour WS Jr, Berge TO, Tigertt WD: The comparative pathology of experimental Venezuelan equine encephalomyelitis infection in different animal hosts. J Infect Dis 1962; 110: 80-97.